Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

Int J Biol Markers. 2013 Dec 17;28(4):e336-47. doi: 10.5301/jbm.5000041.

PMID:
23999848
2.

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, Albrile F, Bobbio M, Merlano M.

Int J Cardiol. 2011 Apr 14;148(2):194-8. doi: 10.1016/j.ijcard.2009.09.564. Epub 2009 Nov 27.

PMID:
19945181
3.

Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Bejarano Hernández S, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M.

Eur J Cancer. 2015 Nov;51(17):2517-24. doi: 10.1016/j.ejca.2015.08.011. Epub 2015 Aug 27.

PMID:
26321502
4.

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.

Ludovini V, Antognelli C, Rulli A, Foglietta J, Pistola L, Eliana R, Floriani I, Nocentini G, Tofanetti FR, Piattoni S, Minenza E, Talesa VN, Sidoni A, Tonato M, Crinò L, Gori S.

BMC Cancer. 2017 Jul 26;17(1):502. doi: 10.1186/s12885-017-3483-2.

5.

Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.

Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B.

Mol Diagn Ther. 2013 Dec;17(6):371-9. doi: 10.1007/s40291-013-0045-4.

PMID:
23812950
6.

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.

Li H, Hu B, Guo Z, Jiang X, Su X, Zhang X.

Yonsei Med J. 2019 Jan;60(1):30-37. doi: 10.3349/ymj.2019.60.1.30.

7.

Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure.

Zakrzewski-Jakubiak M, de Denus S, Dubé MP, Bélanger F, White M, Turgeon J.

Br J Clin Pharmacol. 2008 May;65(5):742-51. doi: 10.1111/j.1365-2125.2007.03091.x. Epub 2008 Feb 12.

8.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I.

J Clin Oncol. 2004 Aug 1;22(15):3070-9.

PMID:
15284257
9.

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.

Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK.

J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29.

PMID:
18664656
10.

Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

Cardiovasc Toxicol. 2012 Jun;12(2):135-42. doi: 10.1007/s12012-011-9149-4.

PMID:
22189487
11.

Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients.

Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D.

Surg Today. 2011 Apr;41(4):471-6. doi: 10.1007/s00595-009-4310-4. Epub 2011 Mar 23.

PMID:
21431478
12.

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.

J Clin Oncol. 1996 Dec;14(12):3112-20.

PMID:
8955656
13.

Renin-angiotensin-aldosterone system related gene polymorphisms and urinary total arsenic is related to chronic kidney disease.

Chen WJ, Huang YL, Shiue HS, Chen TW, Lin YF, Huang CY, Lin YC, Han BC, Hsueh YM.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):95-102. doi: 10.1016/j.taap.2014.05.011. Epub 2014 Jun 5.

PMID:
24907556
14.

Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.

Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T.

Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):544-552. doi: 10.1093/ehjci/jex159.

PMID:
29106497
15.

Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism.

Vergaro G, Fatini C, Sticchi E, Vassalle C, Gensini G, Ripoli A, Rossignol P, Passino C, Emdin M, Abbate R.

J Cardiovasc Med (Hagerstown). 2015 Jun;16(6):416-22. doi: 10.2459/JCM.0000000000000156.

PMID:
25036270
16.

GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.

Oliveira AL, Rodrigues FF, Santos RE, Aoki T, Rocha MN, Longui CA, Melo MB.

Genet Mol Res. 2010 Jun 11;9(2):1045-53. doi: 10.4238/vol9-2gmr726.

17.

The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.

Nolan L, Darby A, Boleti K, Simmonds P.

Breast. 2011 Apr;20(2):151-4. doi: 10.1016/j.breast.2010.09.001. Epub 2010 Oct 20.

PMID:
20970333
18.

Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population.

Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, Ardaillou R, Soubrier F.

Hypertension. 1999 Sep;34(3):423-9.

PMID:
10489388
19.

Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.

Havsteen H, Brynjolf I, Svahn T, Dombernowsky P, Godtfredsen J, Munck O.

Cancer Chemother Pharmacol. 1989;23(2):101-4.

PMID:
2910506
20.

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L.

J Clin Oncol. 2015 Apr 1;33(10):1136-42. doi: 10.1200/JCO.2014.58.7782. Epub 2015 Feb 23.

Supplemental Content

Support Center